Affordable Access

Publisher Website

The prevalence of HIV-1 DNA in AIDS-related lymphoma and Kaposi Sarcoma throughout the AIDS epidemic

Authors
Journal
Infectious Agents and Cancer
1750-9378
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Volume
7
Identifiers
DOI: 10.1186/1750-9378-7-s1-p43
Keywords
  • Poster Presentation
Disciplines
  • Biology
  • Medicine

Abstract

The prevalence of HIV-1 DNA in AIDS-related lymphoma and Kaposi Sarcoma throughout the AIDS epidemic POSTER PRESENTATION Open Access The prevalence of HIV-1 DNA in AIDS-related lymphoma and Kaposi Sarcoma throughout the AIDS epidemic Leanne C Huysentruyt1,3*, Susanna Lamers2, Michael S McGrath1,3 From 13th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) Bethesda, MD, USA. 7-8 November 2011 Background Chronic inflammation is linked to tumorigenesis for many cancer types and likely contributes to tumor devel- opment in the HIV-infected patient population. AIDS- related lymphoma (ARL) and Kaposi Sarcoma (KS), two AIDS-defining cancers, are associated with the tumor viruses EBV and KSHV, respectively. However, EBV is only detectable in ~40% of ARLs and KSHV alone is not sufficient for KS development. Recent studies have shown that HIV is localized to tumor associated macro- phages (TAM), not malignant B cells, in a portion of EBV-negative ARLs suggesting, that HIV infected TAM may play a role in tumorigenesis. The goal of this research was to determine the prevalence of HIV+ ARL and KS throughout the AIDS epidemic and examine tumor associated HIV for unique genetic signatures. Material and methods Whole genomic amplified DNA from ARL and KS biop- sies was used for quantitative HIV gag gene amplifica- tion. The 3’ env-LTR segment of HIV-1 genomes from tumor and non-tumor tissues from two patients that died of ARL were sequenced and Bayesian phylogenies were inferred using BEAST. All specimens were provided by the AIDS and Cancer Specimen Resource. Results Of the 119 ARL and 91 KS biopsies, 45% and 40% con- tained detectable HIV-1 DNA, respectively. There was a significant decrease in the prevalence of HIV-1 DNA positive ARL and KS cases in the post-HAART era (after 1996; ARL=39%, KS=16.7) as compared to pre- HAART (ARL=54%, KS=45%). Our data suggest the overall amount of HIV DNA is less in tumor biopsies from the post-HAART era. A

There are no comments yet on this publication. Be the first to share your thoughts.